Andrew M. Farland

Hematology

2116 S Hawthorne Rd
Winston Salem, NC 27157

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Transplanted gene-modified placental cells boost FVIII activity in pediatric sheep without eliciting immunity, toxicity, or adverse events.

Transplanted gene-modified placental cells boost FVIII activity in pediatric sheep without eliciting immunity, toxicity, or adverse events.

Journal: Frontiers in immunology

Published: October 01, 2025

Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.

Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.

Journal: Blood advances

Published: April 02, 2024

A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.

A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.

Journal: Research and practice in thrombosis and haemostasis

Published: February 09, 2024

A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.

A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.

Journal: Blood advances

Published: May 24, 2023

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII.

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII.

Journal: Frontiers in immunology

Published: May 27, 2022

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity.

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity.

Journal: Nature communications

Published: April 19, 2022

Race, rituximab, and relapse in TTP.

Race, rituximab, and relapse in TTP.

Journal: Blood

Published: April 18, 2022

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.

Journal: Frontiers in cell and developmental biology

Published: March 18, 2021

Implementation of Individualized Pain Care Plans Decreases Length of Stay and Hospital Admission Rates for High Utilizing Adults with Sickle Cell Disease.

Implementation of Individualized Pain Care Plans Decreases Length of Stay and Hospital Admission Rates for High Utilizing Adults with Sickle Cell Disease.

Journal: Pain medicine (Malden, Mass.)

Published: March 10, 2021

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A.

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A.

Journal: Frontiers in bioengineering and biotechnology

Published: December 08, 2020

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A.

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A.

Journal: Molecular therapy. Methods & clinical development

Published: February 19, 2020

Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report.

Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: February 20, 2018

Showing 1-12 of 15

Last Updated: 09/26/2026